{"id":"W2790338852","doi":"10.1158/1538-7445.sabcs17-ot3-04-04","title":"Abstract OT3-04-04: LUCY: A phase IIIb, single-arm, open-label multicenter study of olaparib in patients with HER2-negative metastatic breast cancer and a germline <i>BRCA1/2</i> mutation","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Olaparib; Medicine; Metastatic breast cancer; Internal medicine; BRCA mutation; Oncology; PARP inhibitor; Hazard ratio; Breast cancer; Taxane; Progression-free survival; Eribulin; Cancer; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003367646,0.001653581,0.002510974,0.0003749786,0.0006292759,0.001195576,0.00131146,0.001965558,0.007983106],"category_scores_gemma":[0.001477087,0.0006721626,0.001823366,0.0005535276,0.001751636,0.00114311,0.0005495732,0.003596062,0.002078502],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009955666,"about_ca_system_score_gemma":0.003053906,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00125626,"about_ca_topic_score_gemma":0.002643705,"domain_scores_codex":[0.9989892,0.0005854532,0.00003405985,0.0001510009,0.00007903104,0.0001612739],"domain_scores_gemma":[0.9985696,0.0002099225,0.000292144,0.0000927779,0.00009786074,0.0007376867],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.89204,0.04052654,0.004004588,0.0009533039,0.001104097,0.0001768385,0.0001634546,0.001115858,0.0113441,0.000285487,0.008058655,0.040227],"study_design_scores_gemma":[0.8136685,0.1783317,0.004121265,0.00003902159,0.0002706391,0.0001039945,0.00002936148,0.000589669,0.0006912083,0.0001809314,0.001947914,0.00002579457],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9679509,0.007435106,0.001555279,0.002924829,0.0004813622,0.009031164,0.005474597,0.0004054079,0.004741302],"genre_scores_gemma":[0.9680293,0.002720938,0.003817604,0.003994621,0.0006669102,0.009885029,0.004808992,0.00008708163,0.005989512],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007983106,"threshold_uncertainty_score":0.02670622,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1309637611548154,"score_gpt":0.46960491233777,"score_spread":0.3386411511829547,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}